FDA QMSR 2026
Is your manufacturing quality system inspection-ready?
The FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026. It incorporates ISO 13485:2016 into the medical device quality framework – and FDA inspections now follow an updated, risk-based process.
In effect since
February 2, 2026
Incorporated by reference
ISO 13485:2016
New inspection process
CP 7382.850 replaces QSIT
What changed
A new regulation – and a new way of inspecting.
For most manufacturers, the QMSR is less about new paperwork and more about evidence: does your quality system work, is it driven by risk, and can you show it?
01
ISO 13485:2016 is now the framework
21 CFR Part 820 now incorporates ISO 13485:2016 by reference, together with the terms and definitions of ISO 9000:2015. Where they conflict, the FD&C Act and FDA’s regulations take precedence – so FDA-specific requirements still apply on top.
02
Risk management runs through everything
The QMSR specifically requires risk management. Risk is expected to drive decisions across the whole quality system – from design and production to suppliers, complaints and CAPA.
03
QSIT is retired
Since February 2, 2026, FDA investigators use Compliance Program 7382.850. Inspections are organized around six QMS areas and follow patient and user risk – and the scope can expand when problems are found.
04
Your internal records are in scope
Management review records, internal audit results and supplier audit reports are no longer off-limits. Investigators can read them to judge whether your oversight is effective – not just documented.
Early inspection findings
Where FDA is finding gaps.
In May 2026, an FDA official shared the most common Form 483 observations from the first QMSR inspections (February to mid-April 2026):
Source: RAPS Regulatory Focus, May 2026
- Risk management – the top observation
- Outsourcing and purchasing controls
- Complaint handling
- Corrective actions
- Unique device identification (UDI) systems
How qteam service LLC helps
From gap assessment to inspection day.
We support medical device manufacturers with hands-on, experienced help – exactly where your team needs it.
01
Quality system gap assessment
A structured review of your QMS against the QMSR, ISO 13485:2016 and the remaining FDA-specific requirements – including procedures, records and how risk management is applied in practice.
02
Remediation planning
A prioritized, risk-based roadmap to close the gaps: clear owners, realistic timelines and the documentation updates that matter most for your next inspection.
03
CAPA effectiveness
Root-cause analysis, actions and effectiveness checks that stand up to scrutiny – so CAPAs actually prevent recurrence instead of only closing on paper.
04
Supplier quality
Risk-based controls for suppliers and outsourced processes: selection and evaluation, quality agreements, supplier audits and monitoring.
05
Inspection preparation
Mock and test inspections along the six QMS areas of CP 7382.850, behavior training for your teams, and unannounced test audits. More about our trainings
Not sure where to start?
Let’s talk – the first 30 minutes are free.
A free, no-obligation introductory consultation is the easiest way to find out where your quality system stands.
Quick self-check
Six questions to ask your team this week.
If you cannot answer every question with a confident “yes”, a free 30-minute conversation is a good place to start.
- Have your quality manual, procedures and training been updated from the old QSR to the QMSR and ISO 13485:2016?
- Is risk management applied across all processes – and can you show how it drives decisions?
- Would your management review and internal audit records hold up if an FDA investigator read them?
- Are suppliers and outsourced processes controlled according to their risk?
- Do your CAPAs include verified effectiveness checks?
- Are complaint handling, MDR reporting and UDI processes complete and aligned?
Free download
The FDA QMSR readiness checklist.
A practical two-page checklist to review your quality system against the QMSR and the six QMS areas FDA now inspects under Compliance Program 7382.850 – ready to use in your next internal audit or management review.
- QMS foundation – ISO 13485:2016, FDA-specific requirements, procedures and training
- Management oversight – management review, internal audits, quality objectives
- Design and development, production and service provision
- Outsourcing and purchasing, change control
- Measurement, analysis and improvement – complaints, MDR, CAPA, UDI
Prefer an independent view? See our service sheet QMSR gap assessment (PDF).
Get your free copy
How it works
Three steps to clarity.
Step 1
Free 30-minute introductory consultation
We talk about your devices, your quality system and any upcoming audits or inspections – and where you see the biggest risks.
Step 2
Focused assessment
We agree on a scope that fits your situation – from a targeted review of one area to a full QMSR gap assessment.
Step 3
Roadmap and support
You receive clear findings and a prioritized plan. We can support the remediation and prepare your team for inspection day.
Let’s talk
Schedule your free 30-minute introductory consultation.
The first 30 minutes are free of charge and without obligation. Pick a time that suits you in our online calendar – you will receive a confirmation with a Microsoft Teams link.
Online booking via Microsoft Bookings – or send us a message or email info@qteam-service-llc.com · qteam service LLC, 13355 Noel Rd, Ste 1100, Dallas, TX 75240
Sources: FDA – Quality Management System Regulation (QMSR) · FDA – QMSR Frequently Asked Questions · RAPS – FDA official details top observations from QMSR inspections. This page provides general information and is not legal or regulatory advice.
English 
German 
French 
Italian 
Spanish